Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > REGULATORY
REGULATORY
- Subcommittee to Recommend Use of Most-recent 3-year Averages in Drug Cost Calculation
October 26, 2011
- Chuikyo Subcommittee Approves Revision of Foreign Price Adjustment Rule
October 26, 2011
- Korosho to Take Stricter Look at Companies’ Market Size Forecasts
October 26, 2011
- JMA, JPA Oppose Increase in Patients’ Copayments for OTC-like Drugs
October 26, 2011
- TPP Could Have Major Impact on NHI Price System: Ms Weatherall of University of Queensland
October 26, 2011
- Patent Office to Revise Rules for Granting Patent Extensions
October 25, 2011
- Supreme Court Upholds Ban on Reimbursement in “Mixed Healthcare”
October 25, 2011
- New Rules for Application of GCP Ordinance to Take Effect April 1, 2012
October 25, 2011
- EMA Confirms Usefulness of Pioglitazone-Containing Medicines as 2nd, 3rd Line Treatment Options: Takeda
October 24, 2011
- Survey Finds Slight Increase in Generic Drug Dispensing Rate
October 24, 2011
- Korosho Receives 270 Requests for Development of Unapproved Drugs, Indications in 2nd Round
October 24, 2011
- Groups of Care Providers, Patients Against Creating Compensation System for Injury from Anticancer Drugs
October 22, 2011
- Drug Discovery Support Agency Will Not Compete with Private Sector: Mr Tsuchiya
October 21, 2011
- CSIMC Recommended Approval for Reimbursement on Piecework for 2 High-Priced Drugs
October 21, 2011
- Survey Finds Slight Increase in Generic Drug Dispensing Rate
October 21, 2011
- MHLW to Review Premium System Placing Priority on Premium for Pediatric Use
October 20, 2011
- Mr Kobayashi of Chuikyo Insists on NHI Price Reductions for New Generics
October 20, 2011
- MHLW Subcommittee Agrees on Access System for Domestically Unapproved Drugs
October 20, 2011
- MHLW Presents Data at Chuikyo Supporting Reduction in 70% Rule for New Generics
October 20, 2011
- Cost of Advanced Healthcare Services Totaled ¥13.2 Billion in FY2010: Korosho
October 20, 2011
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…